Targeting CRISPR–Cas9 at centromeric retrotransposons in hexaploid bread wheat reconfigured up to 11 chromosomes in a single generation, yielding translocations, isochromosomes and aneuploids.
“My hope is that one day Origin Genomics can help couples and families with these hereditary diseases not pass them down to their children, and still have as many healthy children as they’d like,” Tie said, according to the Origin…
A United Nations initiative aspires to make large pharmaceutical companies pay for the commercial use of genetic data
A biotech entrepreneur has raised $30 million to launch Preventive, a public-benefit company dedicated to studying whether gene-edited babies can be made safely—the largest known investment yet in the field of heritable genome editing, as MIT Technology Review’s Antonio Regalado…
Imagine receiving a single treatment that could keep your cholesterol under control for decades, potentially eliminating the need for daily medication. Advances in gene editing are bringing that possibility closer to reality. But scientists say the same technology that could…
Gene Therapy (2026) Cite this article Following the 2020 PRISMA guidelines, we conducted a systematic review of 21 key clinical and preclinical studies (published during 2014–2026) to evaluate CRISPR/Cas9-mediated gene editing in β-thal and SCD. The inclusion criteria focused on studies reporting foetal…
In 2023, the FDA approved CASGEVY, the first treatment in the United States to use CRISPR gene-editing technology. The treatment is used for certain patients with sickle cell disease, a genetic blood disorder that can cause severe pain and other complications.
For years, scientists have been working on ways to treat genetic disorders that cause serious health problems. Now, a Phase 1/2 clinical trial is testing an experimental prime-editing treatment called PM577a. So far, only one patient has received the treatment, and the…
Researchers are exploring the use of germline stem cell (GSC) culture and transplantation as a method to improve genome editing in finfish aquaculture. This approach aims to address current limitations in the industry by allowing scientists to introduce, validate, and…
In recent years, significant milestones have been achieved in CRISPR therapies (Figure 1), including the first in vivo base-editing successes, the approval of CASGEVY, and late-stage clinical progress for in vivo gene editing. Genomic safety has continued to be a critical…
Responsible biotech, lab safeguards, and mitigating misuse risks.
An article joins this feed when it matches these terms. Each one is also a search of its own.